期刊文献+

叉头框蛋白C2及胶质瘤相关癌基因同源蛋白-1表达与非小细胞肺癌相关性研究 被引量:3

Correlation Between Expression of Forkhead Box Protein C2, Glioma-associated Oncogene Homolog-1 and Non-small Cell Lung Cancer
下载PDF
导出
摘要 目的探究叉头框蛋白C2(FOXC2)、胶质瘤相关癌基因同源蛋白-1(Gli-1)表达与非小细胞肺癌(NSCLC)相关性。方法选取2015年6月至2018年8月我院NSCLC患者79例作为研究对象,通过免疫组化法测定FOXC2、Gli-1,并分析其与NSCLC相关性。结果 NSCLC组织中FOXC2、Gli-1阳性表达率高于癌旁组织(P<0.05);Ⅰ期NSCLC组织中FOXC2、Gli-1阳性表达率低于Ⅱ~Ⅲ期(P<0.05);有淋巴结转移NSCLC组织中FOXC2、Gli-1阳性表达高于无淋巴结转移(P<0.05);FOXC2、Gli-1阳性表达与NSCLC呈正相关(r_1=0.431,r_2=0.404,均P<0.05)。结论 NSCLC组织中FOXC2、Gli-1阳性表达率较高,其异常表达与淋巴结转移、临床分期相关,有助于评估NSCLC转移能力及预后。 Objective To investigate the correlation between the expression of forkhead box protein C2(FOXC2)and glioma-associated oncogene homologous protein-1(Gli-1)and non-small cell lung cancer(NSCLC).Methods A total of 79 patients with NSCLC from June 2015 to August 2018 were enrolled in this study.FOXC2 and Gli-1 were determined by immunohistochemistry and their correlation with NSCLC was analyzed.Results The positive expression rate of FOXC2 and Gli-1 in NSCLC tissues was higher than that in adjacent tissues(P<0.05).The positive expression rate of FOXC2 and Gli-1 in stage I NSCLC tissues was lower than that in stage II^III(P<0.05).The positive expression of FOXC2 and Gli-1 in metastasis of NSCLC tissues was higher than that without lymph node metastasis(P<0.05).The positive expression of FOXC2 and Gli-1 was positively correlated with NSCLC(r1=0.431,r2=0.404,P<0.05).Conclusion The positive expression rate of FOXC2 and Gli-1 in NSCLC tissues is high.The abnormal expression is associated with lymph node metastasis and clinical stage,which is helpful to evaluate the metastatic ability and prognosis of NSCLC.
作者 闵志雪 MIN Zhi-xue(Department of Pathology,Zhengzhou Third People’s Hospital,Zhengzhou450000 China)
出处 《内蒙古医学杂志》 2019年第4期396-398,共3页 Inner Mongolia Medical Journal
基金 河南省科技攻关计划项目(编号:172102310418)
关键词 非小细胞肺癌 FOXC2 Gli-1 non-small cell lung cancer FOXC2 Gli-1
  • 相关文献

参考文献6

二级参考文献23

  • 1陈鲲,李明珠,李淼,李建华.Twist、E-cadherin和Vimentin在非小细胞肺癌中的表达及意义[J].辽宁大学学报(自然科学版),2011,38(3):235-240. 被引量:7
  • 2Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29.
  • 3Varughese S, Jahangir KS, Simpson CE, et al. A paradigm shift in the treatment of advanced non-small cell lung cancer[J]. Am J Med Sci, 2012, 344(2): 147-50.
  • 4Siegfried JM, Gubish CT, Rothstein ME, et al. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer[J]. J Thorac Oncol, 2012, 7(3): 485-95.
  • 5Nolen BM, Brand RE, Prosser D, et al. Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a largeprospective cohort study[J]. PLoS One, 2014, 9(4): e94928.
  • 6Lou E, Johnson M, Sima C, et al. Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer[J].Cancer Biomark, 2014, 14(4): 207-14.
  • 7Fiala O, Pesek M, Finek J, et al. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib[J]. Anticancer Res, 2014, 34(6): 3205-10.
  • 8Moreira AL, Eng J. Personalized therapy for lung cancer[J]. Chest, 2014, 146(6): 1649-57.
  • 9Pang L, Wang J, Jiang Y, et al. Decreased levels of serum cytokeratin 19 fragment CYFRA 21-1 predict objective response to chemotherapy in patients with non-small cell lung cancer[J]. Exp Ther Med, 2013, 6(2): 355-60.
  • 10Dai H, Liu J, Liang L, et al. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers[J]. Respirology, 2014, 19(5): 707-13.

共引文献136

同被引文献27

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部